In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org). Since then public usage of the system (not including ITN staff and collaborators) has increased dramatically with over 100 new users registering and 3000 total page hits by public users. While the RAVE study accounts for about one third of the study specific page hits, visits to other public studies have increased as well. ITN looks forward to continued expansion of data sharing through TrialShare and welcomes feedback from all of our users (trialsharesupport@immunetolerance.org).
Total Public TrialShare Hits by Date
